Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,659 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia; Psychosis Clear all
Completed Phase 2 Interventional Results available

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCT02237235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
MMFS-202-302, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

New Drugs in the Treatment of Mood Disorders

NCT00001482
View directory record Official record
Conditions
Anxiety Disorder, Mood Disorder, Psychotic Disorder
Interventions
Lamotrigine (Lamictal® (Registered Trademark), Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 10:34 AM EDT
Terminated Phase 3 Interventional Results available

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

NCT03892889
View directory record Official record
Conditions
Schizophrenia
Interventions
Abilify MyCite®
Combination Product
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
68
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families

NCT00924976
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Steps for Achieving Financial Empowerment (SAFE)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional

Transcranial Direct Current Stimulation and Effects on Early Auditory Processing in Schizophrenia

NCT03537703
View directory record Official record
Conditions
Schizophrenia
Interventions
Active tDCS + Auditory Training, Active tDCS + Control Condition, Sham tDCS + Auditory Training
Combination Product
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Phase 3 Interventional

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCT05304767
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 15, 2026, 10:34 AM EDT
Active, not recruiting Not applicable Interventional

CBT-I to Improve Functional Outcomes in Veterans With Psychosis

NCT04646200
View directory record Official record
Conditions
Insomnia, Psychosis
Interventions
Cognitive Behavioral Therapy-Insomnia, Health and Wellness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCT04846881
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Implementing mHealth for Schizophrenia in Community Mental Health Settings

NCT04147897
View directory record Official record
Conditions
Schizophrenia
Interventions
FOCUS
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Chehalis, Washington • Colville, Washington • Everett, Washington + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Virtual Reality Job Interview Training in Severe Mental Illness

NCT03049813
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depressive Disorder
Interventions
Virtual Reality Job Interview Training, Supported Employment (Services as Usual)
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 15, 2026, 10:34 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Cognitive Strategies in Early Psychosis 1

NCT07231497
View directory record Official record
Conditions
Cognition, Healthy Participants
Interventions
Modafinil
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 15, 2026, 10:34 AM EDT
Not yet recruiting Not applicable Interventional

LIFU Effects & Outcomes: Mechanisms Evaluating Striatal Systems Imaging (LEO MESSI)

NCT07710989
View directory record Official record
Conditions
Schizophrenia, Auditory Hallucinations
Interventions
LIFU
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

NCT05145413
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
79
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pfizer/IVGTT/Ziprasidone/Olanzapine

NCT00205725
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 15, 2026, 10:34 AM EDT
Terminated Phase 4 Interventional

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

NCT00169091
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Haloperidol
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

NCT04846868
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Garden Grove, California • La Habra, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Improving Cognition in Schizophrenia Using tDCS

NCT02539797
View directory record Official record
Conditions
Schizophrenia
Interventions
tDCS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Phase 3 Interventional

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

NCT00051298
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
24
States / cities
Little Rock, Arkansas • Cerritos, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

NCT00921804
View directory record Official record
Conditions
Schizophrenia
Interventions
AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Garden Grove, California • Glendale, California • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2010 · Synced Oct 15, 2026, 10:34 AM EDT
Not listed Not applicable Interventional

Cognitive Remediation in Supported Employment at Human Service Center (HSC)

NCT00138021
View directory record Official record
Conditions
Vocational Rehabilitation, Schizophrenia, Mental Disorders, Cognitive Symptoms
Interventions
Computerized cognitive training program
Device
Lead sponsor
Human Service Center, Illinois
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2007 · Synced Oct 15, 2026, 10:34 AM EDT
Completed No phase listed Observational

Effect of Antipsychotics on Appetite Regulation

NCT00903916
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2

NCT01052714
View directory record Official record
Conditions
Diabetes, Obesity, Weight Gain
Interventions
Lifestyle Balance
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Long Beach, California • Sepulveda, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Not applicable Interventional Results available

Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade

NCT00225498
View directory record Official record
Conditions
Schizophrenia
Interventions
ziprasidone vs risperidone or olanzapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 15, 2026, 10:34 AM EDT
Completed Phase 3 Interventional

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

NCT00001768
View directory record Official record
Conditions
Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
Interventions
Intravenous immunoglobulin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 10:34 AM EDT